The aim of the study was to identify optimal combination of circulating biomarkers for cardiovascular outcomes in full or partial remission patients with lymphoproliferative diseases. Method: One hundred eighty two out subjects with full or partial remission of limphoproliferative diseases (43 patients with multiple myeloma, 101 subjects with chronic lymphoid leukemia, and 10 patients with Hodgkin's and nonHodgkin's lymphoma) who underwent cardiac computer tomography (CT) angiography and documented coronary artery disease (CAD) were enrolled in the study. Healthy volunteers (n=52) matched age and sex were referred as control. All subjects gave their written informed consent to participation in the study.
Introduction
Recent clinical studies have been shown an elevated risk of developing of cardiovascular diseases and atherotrombotic events in patients with lymphoma and multiple myeloma [2] . Many of the biomarkers were positively correlated with outcomes in generally population as well as subjects with documented coronary artery disease (CAD) [8, 9] . Cytokines and autoantibodies that have an important role in pathogenesis of lymphoma can be used as prognostic markers [11] . However, their role as predictors of cardiovascular outcomes is controversy. The aim of the study was to identify optimal combination of circulating biomarkers for cardiovascular outcomes in full or partial remission patients with lymphoproliferative diseases.
Design and Methods
One hundred eighty two out subjects with full or partial remission of limphoproliferative diseases (43 patients with multiple myeloma, 101 subjects with chronic lymphoid leukemia, and 10 patients with Hodgkin's and non-Hodg-kin's lymphoma) who underwent cardiac computer tomography (CT) angiography and documented coronary artery disease (CAD) were enrolled in the study. Healthy volunteers (n=52) matched age and sex were referred as control. All subjects gave their written informed consent to participation in the study. Diagnosis and staging of limphoproliferative diseases were defined by current clinical practice guidelines [10, 12] . To be achieving remission chemotherapy with FC, COP, CHOP, mini-CHOP, R-CHOP, R-FC was used accordingly contemporary clinical guidelines. All subjects were at full or partial remission stage at baseline.
Echocardiography in B-mode was performed accordingly to Recommendation of American Society of Echocardiography on the scanner "MyLab 50" (Italy) using a transducer with a frequency of 2.5-3.5 MHz. Enddiastolic and end-systolic LV volumes were obtained using a two-dimensional reference sector according to Simpson's method, and LV ejection fraction (LVEF) was calculated by accordingly conventional methods [7] .
Coronary vessel-wall, and plaque geometrical, and compositional parameters were measured on contrast-enhanced spiral computer tomography (CT) angiography [5] . Contrast-enhanced spiral CT was performed on the "OPTIMA CT 660" scanner (GE Medical Systems, and Milwaukee, USA) with 2 rows of detectors (32 × 2 CT system) during the end-expiratory breath-hold. After noncontrast localization image acquisition, injection of nonionic contrast "Omnipak" (Amersham Health, Ireland) was used to determine the optimal coronary arterial image. Standardized calcium scores were obtained with beam energy of 120 kV, full rotation time of 350 milliseconds, and tube current of 300 mA. The images were reconstructed in 0.6-mm axial slices. Scans were electrocardiogram-gated and were triggered at either 40% or 75% phase contingent on heart rate.
All blood samples were collected after fasting in cooling vacutaner and after that it was immediately centrifugated (4°C for 6.000 × 15 min). After centrifugation serum was blind coded and stored at -70° until used. Human Gal-3, VE-catherin, and NT-pro-brain natriuretic peptide (BNP) were measured by ELISA technique (ELISA kits manufactured by R&G, United Kingdom) used for examination. All determinations were done by duplicating. Fasting plasma glucose (FPG) was quantified by the glucose oxidase procedure; HbA1c was measured by ion-exchange high-performance liquid chromatography (HPLC; BioRad, Hercules, CA, USA).
Concentrations of total cholesterol (TC) and high density lipoprotein (HDL) cholesterol were determined by a Dimension Clinical Chemistry System (Dade Behring Inc, Newark, NJ). Low density lipoprotein (LDL) cholesterol was calculated by using the formula of Friedewald W.T., Levy R.I., Fredrickson D.S. (1972) . All measurements and blood sample for were collected at the same visit.
Clinical Events: Screening and Diagnostics Clinical interviews were carried out every month for three years after baseline. The following are the clinical events verified: newly diagnosed strokes or TIAs; death for any reasons and sudden cardiac death; coronary ischemic events (myocardial infarction, unstable angina) that needed hospital admission for cardiovascular reasons, new-onset chronic heart failure. Newly diagnosed strokes were confirmed with CT. All clinical events were presented as cumulative.
Statistics analysis
Continuous data are expressed as mean and 95% confidence interval (CI). Comparison between groups of continuous variables was tested by unpaired t test. Each variable was evaluated by using Cox proportional hazard survival analysis for cardiac death. The univariate variables that had significant difference with the occurrence of a cardiac death were identified. Multivariate analysis of the univariate variables was then performed and adjusted for age and sex to identify independent predictors of cardiac death with each model (p< 0.05). C-statistics, integrated discrimination indices (IDI) and net-reclassification improvement (NRI) were utilized for prediction performance analyses. Odds ratio (OR) and 95% confidence interval (95% CI) were calculated for all the independent predictors of survival of the patients.
Results
The study population was followed-up for a mean of 36 months. One hundred ninety six cumulative clinical events occurred in 42 patients (23.1%) within the follow-up, with their distribution being as follows: 29 deaths, 65 cardiac arrhythmias, 17 cardiac ischemic events, 9 strokes (5 lacunar infarctions and 2 cardioembolic strokes), 37 CHF and 39 hospital admissions for cardiovascular reasons. No cardiovascular incidences were determined in control cohort patients. There was no significant difference between both cohorts in demographics and haemodynamic, whereas circulating biomarkers of heart failure (NT-pro-BNP and VE-catherin) were increased in subjects with limphoproliferative diseases. Twenty patients (11%) with limphoproliferative diseases were hypertensive, thirty nine subjects (21.4%) were dyslipidemic, fourty two (23.1%) were obese and twenty two patients (12.1%) had type two diabetes mellitus.
In the age-and sex-adjusted univariate (backward stepwise) analysis Gal-3 and NT-pro-BNP had a strongest impact on cardiovascular incidences amongst comorbidities, hemodynamic, other biomarker variables as shown in Table 2 . In multivariable analysis, Gal-3, NT-pro-BNP, and VE-catherin remained to be independent predictors for cardiovascular incidences.
Using reclassification methods, however, it was found that the addition of NT-pro-BNP to the ABC model (Gal-3) improved the relative IDI by 6.9% for cardiovascular incidences (Table 3) . Adding combination of two biomarkers (NTpro-BNP + VE-catherin) to ABC model improved the relative IDI by 9.1% for cardiovascular incidences. For category-free NRI, 12% of events (p=0.001) and 20% of non-events (p=0.001) were correctly reclassified by the addition of NTpro-BNP + VE-catherin to the ABC model for cardiovascular incidences (Table  4) . Thus, it has suggested that combination of three biomarkers (Gal-3, NT-pro-BNP + VE-catherin) remained statistically significant predictors for cardiovascular incidences within three-year observation.
Discussion
These findings support the current hypothesis that cardiovascular incidences develop in the context of persistent immune stimulation, inflammation and endothelial dysfunction. Gal-3, NT-proBNP are an emerging biomarker of heart failure and of myocardial fibrosis risk [1, 3] . Therefore, Gal-3 seems to play a relevant role in orchestrating distinct cell events in tumor microenvironment and for this reason, it can be considered a target in tumor therapies [6] . VE-catherin is sensitivity biomarker of microvascular injury and endothelial dysfunction [4] . All these biomarkers may have a pivotal role in determination of poor clinical outcomes in full or partial remission patients with lymphoproliferative diseases. In this study, it has aimed to determine the prognostic significance of a large panel of serum biomarkers (Gal-3, NT-pro-BNP + VE-catherin) distinguished traditionally cytokines and autoantibodies and compare them with a control group, and also to see for any relationship with known classical prognostic factors, such as obesity and hypertension. Analysis of obtained outcomes has been revealed that adding NT-pro-BNP + VE-catherin to Gal-3 may improve a predictive value of classical phenotypic biomarker Gal-3. In fact, no any association of predictive value of circulating biomarkers with traditional cardiovascular risk factors, such as diabetes, hypertension, and obesity. A better understanding of the molecular mechanisms regulating endothelial cell junction integrity, tumor progression, and biomechanical heart stress after chemotherapy is required for developing new biomarker score based on measurement of Gal-3, NT-pro-BNP + VE-catherin. Further analysis of the biomarkers identified in this report should enhance our ability to diagnose, monitor and treat this disease.
In conclusion: Combination of Gal-3, NT-pro-BNP + VE-catherin remained statistically significant predictors for cardiovascular incidences within three-year observation. Notes: T2DM -type two diabetes mellitus, GFR -Glomerular filtration rate, HDL-C -high-density lipoprotein cholesterol, LDL-C -low-density lipoprotein cholesterol, BP -blood pressure, BMI -body mass index, BNP -brain natriuretic peptide, LVEF -left ventricular ejection fraction, U -unit, Em -early diastolic myocardial velocity, Аm -late diastolic myocardial velocity, E -peak velocity of early diastolic left ventricular filling, ACEI -angiotensin-converting enzyme inhibitor, ARAs -angiotensin-2 receptors antagonists Note: Model 1-Gal-3; Model 2 -Gal-3 +NT-pro-BNP + VE-catherin. Abbreviations: NRI -net reclassification improvement, BNP -brain natriuretic peptide.
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Limitations of the study. This study has some limitations. We believed that a greater cohort would be desirable to improve the power of the study. We also relied on clinical data to rule out infection and other inflammatory diseases before sampling, but we couldn't exclude that some patients had unrecognized the conditions responsible for the elevated Gal-3 levels, VE-catherin. Therefore, NTproBNP levels may relate with type of chemotherapy that is needed to take into consideration when data are discussed.
